Torky Haitham A, Sherif Ahmed, Abo-Louz Ashraf, Ali Mohamed, Ahmed Ali, Ali Ahmad
Department of Obstetrics and Gynecology, October 6th University, Cairo, Egypt.
Department of Obstetrics and Gynecology, Ain-Shams University, Cairo, Egypt.
Gynecol Obstet Invest. 2018;83(5):461-465. doi: 10.1159/000481798. Epub 2017 Nov 7.
Ovarian cancer is a relatively common occurrence with the formation of a tumour in the ovaries and is the leading cause of death in the gynecological field. Despite enormous efforts, there are no successful screening methods developed until now to decrease mortality in this regard.
To evaluate nidogen-2 as a new tumour marker combined with higher sensitivity, specificity and accuracy than carbohydrate antigen (CA-125) and Doppler ultrasound to improve early diagnosis of ovarian cancer.
One hundred and forty-four qualified women with a preliminary diagnosis of adnexal mass were subjected to history, examination, transvaginal Doppler ultrasound and Quantitative assessment of serum level of CA-125 and nidogen-2 followed by the resection of the masses, which were sent for histopathological examination.
One-hundred and sixteen cases were benign and 28 cases were malignant. The surgical procedures ranged from limited resection to radical hysterectomy. There was a highly significant correlation between both serum nidogen-2 and CA-125 and the results of histopathological examination (p = 0.0001). Serum nidogen-2 had 91.6% sensitivity, 62% specificity, 37.1% positive predictive value, 97.9% negative predictive value and 68% accuracy (p < 0.05).
Nidogen-2 is a new promising ovarian malignancy biomarker that correlates closely with ultrasound and CA125. It did improve the accuracy of diagnosis, but further studies are needed.
卵巢癌是卵巢形成肿瘤的一种相对常见的疾病，是妇科领域的主要死亡原因。尽管付出了巨大努力，但迄今为止尚未开发出成功的筛查方法来降低这方面的死亡率。
评估巢蛋白-2作为一种新的肿瘤标志物，其敏感性、特异性和准确性高于糖类抗原（CA-125）和多普勒超声，以改善卵巢癌的早期诊断。
144名初步诊断为附件包块的合格女性接受了病史采集、检查、经阴道多普勒超声检查以及血清CA-125和巢蛋白-2水平的定量评估，随后切除包块并送去进行组织病理学检查。
116例为良性，28例为恶性。手术方式从有限切除到根治性子宫切除术不等。血清巢蛋白-2和CA-125与组织病理学检查结果之间均存在高度显著相关性（p = 0.0001）。血清巢蛋白-2的敏感性为91.6%，特异性为62%，阳性预测值为37.1%，阴性预测值为97.9%，准确性为68%（p < 0.05）。
巢蛋白-2是一种有前景的新型卵巢恶性肿瘤生物标志物，与超声和CA125密切相关。它确实提高了诊断的准确性，但仍需要进一步研究。
